A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

Zhaojun Sun, Bernard Lethé, Yi Zhang, Vincenzo Russo, Didier Colau, Vincent Stroobant, Thierry Boon, Pierre Van Der Bruggen

Research output: Contribution to journalArticlepeer-review


Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.

Original languageEnglish
Pages (from-to)644-652
Number of pages9
JournalCancer Immunology, Immunotherapy
Issue number6
Publication statusPublished - Jun 2006


  • HLA-A68
  • LAGE-1
  • Peptide
  • Poxvirus
  • SNP
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology


Dive into the research topics of 'A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors'. Together they form a unique fingerprint.

Cite this